Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* Male or female, age ≥ 18 years with chronic HCV and HIV-1 infection~* HCV RNA \> 1 x 10\^4 IU/mL at screening~* Infection with HCV genotype 1, 2 or 3 as determined at screening~* HIV-1 infection confirmed with positive ELISA or Western blot at screening~* Medical records must be sufficient to be categorized on interferon (IFN) eligibility or prior treatment history with PEG/RBV.~* Confirmation of chronic HCV infection~* Ability to determine presence/absence of cirrhosis.~* HIV antiretroviral therapy (ARV) criteria of one of the following:~  * ARV untreated with a CD4 T-cell count \> 500 cells/mm\^3~ * On a stable, protocol-approved, ARV for \> 8 weeks prior to screening with a CD4 T-cell count \> 200 cells/mm\^3 and a documented undetectable plasma HIV-1 RNA level for ≥ 8 weeks preceding the screening visit~* Approved HIV antiretroviral medications based on drug interaction studies~* Not been treated with any investigational drug or device within 30 days of the screening visit~* Females if confirmed that she is not pregnant or nursing of non-childbearing potential or of childbearing potential but has a negative serum pregnancy test at screening and agrees to use protocol approved method of birth control from screening through 6 months after the last dose of RBV~* Males who agree to consistently and correctly use a condom while their female partner agrees to use protocol approved method of birth control from screening through 7 months after the last dose of RBV~* Must be of generally good health as determined by the investigator.~* Liver imaging within 6 months of baseline/Day 1 is required in cirrhotic patients only, to exclude hepatocellular carcinoma (HCC)~Exclusion Criteria:~* Non-genotype 1/2/3 or mixed genotype at screening~* Genotype 1 with prior treatment for HCV~* Poor control with ARV regimen~* Prior exposure to a direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase~* Chronic liver disease of a non-HCV etiology (eg, hemochromatosis, Wilson's disease, α1 antitrypsin deficiency, cholangitis)~* A new AIDS-defining condition diagnosed within 30 days prior to screening~* Active, serious infection (other than HIV or HCV) requiring parenteral antibiotics, antivirals or antifungals within 30 days prior to baseline~* Infection with hepatitis B virus (HBV)~* Contraindication to RBV therapy~* Chronic use of systemically administered immunosuppressive agents (eg, prednisone equivalent \> 10 mg/day)~* History of solid organ transplantation or malignancy diagnosed or treated within 5 years~* Current or prior history of clinical hepatic decompensation or other significant gastrointestinal disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+RBV 12 Weeks (GT 2/3, TN) (Type: EXPERIMENTAL): Treatment-naive (TN) participants coinfected with HIV-1 and genotype (GT) 2 or genotype 3 HCV infection will receive SOF+RBV for 12 weeks.
- SOF+RBV 24 Weeks (GT 2/3, TE) (Type: EXPERIMENTAL): Treatment-experienced (TE) participants coinfected with HIV-1 and genotype 2 or genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
- SOF+RBV 24 Weeks (GT 1, TN) (Type: EXPERIMENTAL): Treatment-naive (TN) participants coinfected with HIV-1 and genotype 1 HCV infection will receive SOF+RBV for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).